|
|
|
|
| LEADER |
01812nam a22002895i 4500 |
| 001 |
000294825 |
| 005 |
20210621082505.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130531s2010 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781441966094
|
| 024 |
7 |
|
|a 10.1007/978-1-4419-6609-4
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Vascular Disruptive Agents for the Treatment of Cancer /
|c edited by Tim Meyer.
|
| 250 |
|
|
|a 1st ed. 2010.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2010.
|
| 300 |
|
|
|a IX, 256 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Development of Vascular Disrupting Agents -- Development of Vascular Disrupting Agents -- Pre-Clinical Development -- The Discovery and Characterisation of Tumour Endothelial Markers -- The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs) -- Combination Therapy with Chemotherapy and VDAs -- Lessons from Animal Imaging in Preclinical Models -- Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action -- Imaging in the Development of Vascular Disruptive Agents -- MRI to Assess Vascular Disruptive Agents -- Contrast Ultrasound in Imaging Tumor Angiogenesis -- Clinical Development -- The Clinical Development of Tubulin Binding Vascular Disrupting Agents -- ASA404 (DMXAA): New Concepts in Tumour Vascular Targeting Therapy -- Vascular Disruptive Agents in Combination with Radiotherapy.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
|
|a Meyer, Tim.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|